Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,972,192 shares, an increase of 47.6% from the August 31st total of 2,013,511 shares. Based on an average daily trading volume, of 3,758,535 shares, the short-interest ratio is presently 0.8 days. Currently, 4.4% of the shares of the stock are short sold.

Separately, FBR & Co reiterated a “buy” rating on shares of Immune Pharmaceuticals in a research note on Thursday, August 18th.

Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 0.266 on Wednesday. The firm’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.38. Immune Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $1.54. The company’s market capitalization is $21.06 million.

Immune Pharmaceuticals (NASDAQ:IMNP) last posted its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Equities analysts predict that Immune Pharmaceuticals will post ($0.56) EPS for the current fiscal year.

In related news, Director Daniel Kazado purchased 666,667 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $300,000.15. Following the completion of the purchase, the director now owns 907,290 shares in the company, valued at approximately $408,280.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Gedeon Teper purchased 937,500 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was bought at an average price of $0.38 per share, with a total value of $356,250.00. Following the completion of the purchase, the chief executive officer now owns 5,748,405 shares of the company’s stock, valued at approximately $2,184,393.90. The disclosure for this purchase can be found here. 17.83% of the stock is owned by corporate insiders.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

5 Day Chart for NASDAQ:IMNP

Receive News & Stock Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.